The Vehicle Is the Therapy: Next-Gen Capsid and LNP Engineering for Precision Delivery
08 Sept 2026
Next Gen Vector Engineering & Delivery
- As tissue-specific delivery becomes the differentiator, where is the higher-leverage investment: rational or directed-evolution capsid engineering for AAV, or ligand- and lipid-tuned LNPs for redosable, targeted RNA delivery? Or Where are current delivery systems (e.g., LNPs, viral vectors) falling short—and what innovations will define next‑generation targeting and tissue specificity?
- Which analytical technologies are now good enough to close the design–build–test loop quickly — distinguishing full vs. empty capsids, confirming LNP RNA encapsulation and integrity, and verifying payload identity — so vector engineering becomes data-driven rather than empirical?
- What design strategies — capsid de-immunization, novel serotypes, ionizable lipid chemistry, PEG alternatives — are most promising for enabling redosing and managing pre-existing or anti-vector immunity, and how do we screen for these traits early?
- How should next-gen vector and LNP designs be constrained by downstream (encapsulation hardware, viral vector productivity, purification) so a promising construct doesn't fail at scale
- How should teams co-optimize nucleic acid design, starting material quality, and delivery system (e.g., LNPs) to improve in vivo performance? IDT/Aldevron Cytiva
- What are the barriers to translating promising vector designs from early development into robust, reproducible manufacturing processes?
- Could platforms advance therapies: can we standardize vector design and delivery, or will product-specific optimization remain dominant?
Industry Expert
